RADIANT LOGISTICS ANNOUNCES RESULTS FOR THE SECOND FISCAL QUARTER ENDED DECEMBER 31, 2024
Prnewswire· 2025-02-11 05:05
Continues to deliver solid financial results in face of continued market headwinds;Further progress in green-field and strategic operating partner acquisitions;Well positioned for further growth with untapped $200 million credit facilityRENTON, Wash., Feb. 10, 2025 /PRNewswire/ -- Radiant Logistics, Inc. (NYSE American: RLGT), a technology-enabled global transportation and value-added logistics services company, today reported financial results for the three and six months ended December 31, 2024.Financial ...
Cincinnati Financial Reports Fourth-Quarter and Full-Year 2024 Results
Prnewswire· 2025-02-11 05:05
CINCINNATI, Feb. 10, 2025 /PRNewswire/ -- Cincinnati Financial Corporation (Nasdaq: CINF) today reported: Fourth-quarter 2024 net income of $405 million, or $2.56 per share, compared with $1.183 billion, or $7.50 per share, in the fourth quarter of 2023, after recognizing a $107 million fourth-quarter 2024 after-tax decrease in the fair value of equity securities still held. Full-year 2024 net income of $2.292 billion, or $14.53 per share, compared with $1.843 billion, or $11.66 per share, in 2023. $138 mil ...
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Prnewswire· 2025-02-11 05:05
-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 -- -- Company to discontinue renal basket trial for ADX-097 to conserve resources and evaluate strategic options for its tissue-targeted complement inhibitor platform -- -- Cash runway expected to extend to ...
ROSEN, A RANKED AND LEADING INVESTOR RIGHTS FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
GlobeNewswire· 2025-02-11 05:05
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s September 2023 initial public offering (the “IPO”). If you wish to serve as lead plaintiff, you must move the Court no l ...
REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
GlobeNewswire· 2025-02-11 05:05
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), have until Monday, March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron ...
Astera Labs Announces Financial Results for the Fourth Quarter of Fiscal Year 2024
GlobeNewswire· 2025-02-11 05:05
Record quarterly revenue of $141.1 million, up 25% QoQ and up 179% YoY Fiscal 2024 record revenue of $396.3 million, up 242% versus the prior yearRamping across diverse set of customers and platforms with four product families in fiscal 2025 SANTA CLARA, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for cloud and AI infrastructure, today announced preliminary financial results for the fourth quarter and full fiscal y ...
PennantPark Floating Rate Capital Ltd. Announces Financial Results for the First Quarter Ended December 31, 2024
GlobeNewswire· 2025-02-11 05:05
MIAMI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the first quarter ended December 31, 2024. HIGHLIGHTSQuarter ended December 31, 2024 (Unaudited)($ in millions, except per share amounts) Assets and Liabilities: Investment portfolio (1) $2,193.9 Net assets $962.7 GAAP net asset value per share $11.34 Quarterly increase in GAAP net asset value per share 0.3%Adjusted net asset value per share (2) $11.34 Quarterly increase ...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire· 2025-02-11 05:05
Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power o ...
Cipher Mining Announces Date of Fourth Quarter and Full Year 2024 Business Update Conference Call
GlobeNewswire· 2025-02-11 05:05
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced it will provide a business update and release its fourth quarter and full year 2024 financial results before U.S. markets open on Tuesday, February 25, 2025. Cipher will host a conference call and webcast that day at 8:00 a.m. Eastern Time. The live webcast and a webcast replay of the conference call can be accessed from the investor relations section of Cipher’s website at https://inves ...
iBio Reports Fiscal Second Quarter 2025 Financial Results
GlobeNewswire· 2025-02-11 05:05
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. “In our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,” said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. “Following more recent developments, we also w ...